Effects of an Oral GH Secretagogue (MK-677) on Body Composition and Functional Ability of Older Adults — MOT089  

Aging Clinical Trial

Official title: Effects of an Oral GH Secretagogue (MK-677) on Body Composition and Functional Ability of Older Adults

Status Completed

Clinical Trial Summary

The purpose of this study is to determine whether treatment of healthy older men and women with oral MK-677 for 12 months will enhance pulsatile GH release and increase mean GH and IGF-I concentrations into the range of young adults and will have favorable effects on body composition and functional ability on older adults.

Clinical Trial Description

This is a two year, double-blind, placebo-controlled cross-over trial of once daily administration of MK-677, an oral GH secretagogue, to healthy older adults. During the first year, subjects will be randomized to MK-677 or placebo treatment. In each of three subgroups of subjects (men, women off and women on hormone replacement therapy), 16 subjects will receive MK-677 and 8 will receive placebo. After 1 year, the subjects who received placebo will be switched to MK-677 treatment; the subjects who received MK-677 for the first year will be randomized to either placebo or MK-677 for the second year of the study.The study will test changes in GH, IGF-I, body composition and function. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Aging

• NCT number: NCT00474279
• Study type: Interventional
• Source: University of Virginia
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: July 1998
• Completion date: June 2004